BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Remix Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Remix Therapeutics's drugs run\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06118086-2976@assetmemo.bio
DTSTAMP:20261121T010136Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:REM-422: Phase 1/2 readout est. (NCT06118086)
DESCRIPTION:REM-422\, phase 1/2.\nStudy: Study of REM-422 in Patients With 
 Recurrent\, Metastatic\, or Unresectable Adenoid Cystic Carcinoma\nEstimat
 ed primary completion: 30 September 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/rem-422#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06118086
URL:https://assetmemo.bio/drug/rem-422#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
